Lear Werts files consumer class action case related to Zantac’s hidden cancer risk

Lear Werts files consumer class action case related to Zantac’s hidden cancer risk

Lear Werts has filed the first consumer class action in Missouri against the makers and distributors of the popular stomach-acid drug Zantac: Sanofi-Aventis U.S., Chattem Inc., and Boeheringer Ingelheim Pharmaceuticals. It has been discovered that Zantac, the over-the-counter name of the drug Ranitidine, exposes consumers to the known carcinogen, n-Nitrosodimethylamine (NDMA).

According to a whistle-blower complaint filed in late 2019, testing has revealed that each 150mg tablet of Zantac exposed consumers to 2,511,469 ng of NDMA. This exposure is more than 26,000 times worse than the U.S. Food & Drug Administration’s daily permissible intake limit of 96 ng of NDMA per day. In scientific circles, NDMA has been known to be a dangerous cancer-causing chemical. And NDMA is only used in the United States for research purposes. Indeed, a 1979 study found that NDMA caused cancer in nearly every animal tested in that study.

The class action complaint filed by Lear Werts seeks to recover the money paid by Missouri consumers, who do not have personal injury claims from developing cancer after taking Zantac, for the costs of a medication they never would have paid for had they known that it would expose them to such high levels of NDMA.

Click here to read the complaint.

Lear Werts is also investigating cases where long-time Zantac users have developed cancer, particularly bladder and colo-rectal cancers. If you or someone you know has taken Zantac and developed cancer, please contact the firm regarding what steps are needed to seek compensation from the makers and distributors of Zantac.